CollPlant Biotechnologies Ltd.
CLGN
$2.42
$0.000.00%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -45.15% | -97.55% | 415.52% | -60.55% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -45.15% | -97.55% | 415.52% | -60.55% | |
| Cost of Revenue | -64.81% | -12.85% | 1,146.77% | 5.30% | |
| Gross Profit | 77.22% | -103.00% | -11,750.00% | -51.61% | |
| SG&A Expenses | -10.67% | 7.89% | -27.22% | 8.85% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -22.90% | 3.28% | 13.37% | 1.49% | |
| Operating Income | 21.59% | -177.61% | -8.38% | -3.00% | |
| Income Before Tax | 17.30% | -173.06% | -6.54% | 0.05% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 17.30% | -173.06% | -6.54% | 0.05% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 17.30% | -173.06% | -6.54% | 0.05% | |
| EBIT | 21.59% | -177.61% | -8.38% | -3.00% | |
| EBITDA | 21.99% | -169.75% | -9.17% | -3.42% | |
| EPS Basic | 17.29% | -172.51% | -3.94% | 3.16% | |
| Normalized Basic EPS | 17.31% | -172.51% | -3.94% | -- | |
| EPS Diluted | 17.29% | -175.51% | -3.94% | 3.16% | |
| Normalized Diluted EPS | 17.31% | -175.11% | -3.94% | -- | |
| Average Basic Shares Outstanding | 0.01% | 0.75% | 2.50% | 3.22% | |
| Average Diluted Shares Outstanding | 0.01% | -2.74% | 2.50% | 3.22% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |